GlassScriptPhysician profile
Donna M Seres
NPI 1063453975
$2,337.47
in general payments reported to CMS, 2019-2025
23 companies · $580 in 2025
The $580 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $130 · 2021: $344 · 2022: $451 · 2023: $258 · 2024: $243 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.08 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.86 | 2019-2023 | Qulipta, Lo Loestrin Fe, Orilissa |
| Organon LLC | $455.49 | 2021-2025 | Nexplanon, Nuvaring |
| Astellas Pharma US INC | $297.90 | 2020-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $185.87 | 2023-2025 | |
| Hologic Sales and Service, LLC | $131.48 | 2020-2025 | Thinprep 2000 Processor, Aptima |
| Radius Health, INC. | $118.15 | 2019 | |
| Agile Therapeutics, INC. | $70.73 | 2021-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $63.67 | 2019-2025 | |
| Shield Therapeutics INC | $54.14 | 2024-2025 | |
| Sage Therapeutics, LLC | $47.69 | 2024-2025 | Zurzuvae |
| Allergan, INC. | $42.79 | 2019-2020 | |
| Amgen INC. | $36.62 | 2019-2020 | |
| Avion Pharmaceuticals | $29.85 | 2019-2020 | |
| Conmed Corporation | $27.08 | 2025 | Airseal |
| Therapeuticsmd, INC. | $24.43 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.88 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $15.23 | 2020 | |
| Roche Diagnostics Corporation | $14.91 | 2019 | |
| Sumitomo Pharma America, INC. | $14.82 | 2025 | Myfembree |
| Millicent US INC | $14.04 | 2025 | Femlyv |
| Pfizer INC. | $13.58 | 2022 | |
| Coopersurgical, INC. | $12.72 | 2020 | |
| Acessa Health INC. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Seres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.